• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.48% Nasdaq Down0.45%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    129.63 Up 1.13(0.88%) 3:33PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingMar 31, 2015Dec 31, 2014Sep 30, 2014Jun 30, 2014
    Total Revenue 18,537   24,019   10,972   7,295  
    Cost of Revenue -   -   -   -  
    Gross Profit 18,537   24,019   10,972   7,295  
    Operating Expenses
    Research Development58,035  55,546  46,273  44,672  
    Selling General and Administrative12,724  14,185  9,898  11,518  
    Non Recurring -   -   -  (3,890)
    Others -   -   -   -  
    Total Operating Expenses -   -   -   -  
    Operating Income or Loss (52,222) (45,712) (45,199) (45,005)
    Income from Continuing Operations
    Total Other Income/Expenses Net1,014  2,232  1,277  616  
    Earnings Before Interest And Taxes(51,208)(43,480)(43,922)(44,389)
    Interest Expense -   -   -   -  
    Income Before Tax(51,208)(43,480)(43,922)(44,389)
    Income Tax Expense(431)(22,091)67  (315)
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops(50,777)(21,389)(43,989)(44,074)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income (50,777) (21,389) (43,989) (44,074)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares (50,777) (21,389) (43,989) (44,074)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.